UBS Group
GRNA

UBS Group’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

UBS Group’s Portfolio GRNA Stock Details GRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,379
Closed -$1.9K – 10330
2023
Q2 		$1.9K Sell
6,379
-32,000
-83% -$9.65K ﹤0.01% 7839
2023
Q1 		$16.6K Buy
38,379
+28,216
+278% +$21.7K ﹤0.01% 7229
2022
Q4 		$12K Buy
10,163
+7,363
+263% +$12K ﹤0.01% 8326
2022
Q3 		$7K Buy
2,800
+389
+16% +$1.02K ﹤0.01% 8949
2022
Q2 		$5K Buy
+2,411
New +$16.7K ﹤0.01% 8983
2022
Q1 		– Sell
-1,778
Closed -$18K – 11250
2021
Q4 		$18K Buy
1,778
+1,711
+2,554% +$17K ﹤0.01% 8022
2021
Q3 		$1K Sell
67
-5,013
-99% -$49.1K ﹤0.01% 9333
2021
Q2 		$50K Sell
5,080
-5,280
-51% -$51.5K ﹤0.01% 6438
2021
Q1 		$100K Buy
+10,360
New +$102K ﹤0.01% 5969

UBS Group's GRNA Position: Q3 2023 in Review

UBS Group sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 6,379 shares — an estimated $1.9K sold.

UBS Group first reported a position in GRNA in Q1 2021 and held it in 9 quarters. The position peaked at $100K in Q1 2021. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

  • UBS Group reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 6,379 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $1.9K.
  • UBS Group first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2021 and held it in 9 quarters.
  • UBS Group's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $100K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.